

Serial No.: 09/671,167

Filing Date: 28 SEPTEMBER 2000

Inventor: DAVID A. KIDWELL

NOTICE

The above identified patent application is available for licensing.
Requests for information should be addressed to:

ASSOCIATE COUNSEL (PATENTS)
CODE 1008.2
NAVAL RESEARCH LABORATORY
WASHINGTON DC 20375

ASSOCIATE COUNSEL (PATENTS)
CODE 1008.2
NAVAL RESEARCH LABORATORY
WASHINGTON DC 20375

DTIC QUALITY INSPECTED 3

DISTRIBUTION STATEMENT A
Approved for Public Release
Distribution Unlimited

Docket No.: N.C. 80,182
Inventor's Name: David A. Kidwell

PATENT APPLICATION

1 U.S. Patent No. 5,445,147 issued August 29, 1995; Schoendorfer in U.S. Patent No. 5,465,713
2 issued November 14, 1995; Schoendorfer in U.S. Patent No. 5,638,815 issued June 17, 1997;
3 Schoendorfer in U.S. Patent No. 5,676,144 issued October 14, 1997; Schoendorfer in U.S. Patent
4 No. 5,817,011 issued October 6, 1998; Schoendorfer in U.S. Patent No. 5,817,012 issued
5 October 6, 1998; Schoendorfer, et al in U.S. Patent No. 5,899,856 issued May 4, 1999;
6 Schoendorfer in U.S. Patent No. 5,944,662 issued August 31, 1999; D.E.C. Cole et al, Use of a
7 new sample-collection device (Macroduct™) in anion analysis of human sweat, Clin. Chem. 32
8 (1986) pages 1375-1378; M. Phillips et al, Long-term sweat collection using salt-impregnated
9 pads, J. Invest. Dermatol. 68 (1977) pages 221-224; M. Phillips, An improved adhesive patch
10 for long-term collection of sweat, Biomater. Med. Dev. Artif. Org., 8 (1980) pages 13-21; C.C.
11 Peck, Dermal substance collection device, US Patent 4,706,676, issued November 17, 1987;
12 C.C. Peck, Dermal substance collection device, US Patent 4,960,467, issued October 2, 1990;
13 C.C. Peck, Dermal substance collection device, US Patent 4,819,645, issued April 11, 1989; J.B.
14 Eckenhoff et al, Sweat collection patch, US Patent 4,756,314, issued July 12, 1988; and M.
15 Phillips et al, A sweat-patch test for alcohol consumption: evaluation in continuous and episodic
16 drinkers, Alcohol Clin. Exp. Res., 4 (1980) pages 391-395, all incorporated herein by reference.

17 Generally, sweat collection devices sandwich an absorbent pad between the skin and an
18 outer membrane using a tamper-evident adhesive backing on the membrane. Careful preparation
19 of the skin prior to application of the patch helps reduce the possibility of bacterial growth and
20 previous skin contamination. Non-occlusive membranes allow water vapor to pass through the
21 membrane, which increases comfort for the wearer and allows longer-term wear.

1 One currently commercially available device has combined the non-occlusive membrane
2 with a cellulose collection pad to produce a sweat collection patch. Sweat patches have found
3 wide application in the criminal justice system due to perceived advantages including user
4 friendliness, non-invasiveness, easily observed placement and removal of the sweat patch,
5 detectable adulteration attempts including punctures by needles and attempts to remove the
6 device and either replace it with a new device or the same device, long drug-use detection
7 interval during the wearing of approximately one week, and potential to identify unique
8 metabolites. In addition, there are reports that the sweat patch may either deter or cause
9 individuals to be more forthcoming about drug use.

10 Two reported features of the commercially available sweat patch are first, that the patch
11 appears to protect the skin from contamination by the external environment after being applied,
12 and second, that the skin is cleansed before application of the patch, potentially removing
13 previously deposited drugs. The manufacturer of one commercially available patch states that
14 "passive exposure to ambient drugs of abuse during the wear period is not detected by
15 conventional toxicological analysis of post-wear patches" see Product Package Insert Part #
16 P00020 Revision: A. PHARMCHEK™ Drugs of Abuse Patch For Collection of Cocaine and
17 Cocaine Metabolite, Amphetamines, Opiates, Cannabinoid and Cannabinoid Metabolites, and
18 Phencyclidine (PCP) Through the Skin. PharmChem Laboratories, Inc. Menlo Park, CA. 1999.

19 An article by P. Kintz , Drug Testing in Addicts: a Comparison between Urine, Sweat,
20 and Hair, Therapeutic Drug Monitoring, 18 (1996), incorporated herein by reference, suggested
21 that nonvolatile substances from the environment cannot penetrate the transparent film; a

Docket No.: N.C. 80,182
Inventor's Name: David A. Kidwell

PATENT APPLICATION

1 semipermeable membrane over the pad that allows oxygen, water, and carbon dioxide to pass
2 through the patch, leaving the skin underneath healthy. Further, in M. Burns et al, Monitoring
3 Drug Use with a Sweat Patch: an Experiment with Cocaine, J. Anal. Tox., 19(Jan/Feb) (1994)
4 41-48, incorporated herein by reference, researchers suggested that larger nonvolatile molecules
5 that cannot pass the polyurethane layer remain trapped on the collection pad. Additionally, V.
6 Spiehler et al, Enzyme Immunoassay Validation for Qualitative Detection of Cocaine in Sweat,
7 Clinical Chemistry, 42(1) (1996) 34-38 states that the transparent film portion of the patch allows
8 oxygen, carbon dioxide, and water vapor to escape but prevents the escape of nonvolatile
9 constituents present in sweat. An additional account by G. Skopp, et al, Preliminary Practical
10 Findings on Drug Monitoring by a Transcutaneous Collection Device, J. Forensic Sci., 41(6)
11 (1996) 933-937, stated that molecules larger than vapor-phase isopropanol are excluded by the
12 molecular pore structure (~2 nm) of the plastic membrane. Skopp, et al. used the dye rhodamine
13 B to study the permeability of the sweat patch's polyurethane membrane from Contamination
14 From WithOut, (CFWO), where drugs external to the patch can penetrate the membrane. No
15 CFWO was observed with rhodamine B. However, Skopp et al. used a hydrophilic dye, with
16 both amine and carboxylic acid functional groups. The state of hydration of the inner pad is not
17 reported. If the inner pad was dry, transport of molecules would be reduced and give a false
18 impression of impermeability. Cone, et al., in Sweat Testing for Heroin, Cocaine, and
19 Metabolites, J. Anal. Toxicol. 18 (1994) pages 298-305, incorporated herein by reference,
20 explored CFWO by exposing subjects wearing skin patches to cocaine vapor. They observed
21 some unexpectedly, high concentrations of cocaine (greater than 200 ng per patch), but dismissed

1 them as laboratory handling error "because other patches collected from the same subject under
2 similar conditions were determined to be negative". Furthermore, subjects wore light clothing to
3 cover the patches and were not actively sweating, factors which are predicted to lessen CFWO.

4 The sweat patch is becoming increasingly used in the U.S. criminal justice system to
5 monitor drug use during pretrial and probationary release. Recently, offices of the U.S. Federal
6 Public Defender have described cases where individuals under supervised pretrial or
7 probationary release have had their sweat patch test positive while denying drug use in a credible
8 manner. Cases include individuals with negative urine test results and positive sweat patch
9 results, or close contact with a drug-contaminated environment. Several of these cases involved
10 individuals identified as methamphetamine positive, who denied vehemently any
11 methamphetamine use, some even while admitting they used other illegal drugs. In at least one
12 instance, consecutive 48-hour urine specimens which covered the length of wear of the patch,
13 tested negative while the patch tested positive. A common thread running through these cases
14 was that the individuals were in environments where profuse sweating was commonplace and,
15 frequently, tested positive for drugs with which they had a prior use history and possible
16 environmental contamination.

17 In an article by Kidwell and Smith, Susceptibility of PharmChek™ Drugs of Abuse Patch
18 to Environmental Contamination, NRL Memorandum Report NRL/MR/6170-99-8414,
19 November 3, 1999 and Forensics Science International 2910 (2000) pages 1-18 (attached, in
20 press, volume number, date, and pages are publisher's internal preliminary references and are
21 subject to change at publisher's discretion), both incorporated herein by reference, the authors

1 conclude that both Contamination From WithIn (CFWI), where skin is contaminated with drugs
2 before the application of the sweat patch, and Contamination From WithOut (CFWO), where
3 drugs external to the patch can penetrate the membrane, can occur in the present design for the
4 sweat patches, leading to possible false positive test results.

5 CFWI is distinct from the process where drugs permeate the skin in areas not covered by
6 the patch, enter the blood stream, and are re-excreted in sweat into the patch. Except in extreme
7 cases of external contamination, this is unlikely to occur because, generally speaking, drugs do
8 not enter the bloodstream through skin in high concentrations, see Kidwell and Smith, NRL
9 Memorandum NRL/MR/6170-99-8414, page 13 and Forensics Science International 2910
10 (2000) section 3.2, page 10. For CFWI to be observed, only a source of drugs, a plausible
11 transfer mechanism to the skin, and binding of the drugs to the skin need occur. Because most
12 individuals tested for drug use by the patch are previous drug users, their environment is more
13 likely to be contaminated with drugs, increasing the likelihood that their skin will contact drugs
14 from prior drug using episodes. Because the skin is cleansed using 70% isopropanol swabs
15 before application of the patch, it was thought that prior drug exposures of the skin should not
16 affect the results. D.A. Kidwell et al. Cocaine Detection in a University Population by Hair
17 Analysis and Skin Swab Testing, Forensic Sci. Int., 84 (1997) pages 75-86, incorporated herein
18 by reference, found that 70% isopropanol does not remove all the drug deposited on the skin, and
19 that alcohol combined with a mild acid provided a better solvent for drug removal. A mild acid
20 is one that is suitable for use on human subjects. The people most likely to be tested by the sweat
21 patch are also the most likely to be externally contaminated.

1 Kidwell and Smith, Susceptibility of PharmChek™ Drugs of Abuse Patch to
2 Environmental Contamination, NRL Memorandum Report NRL/MR/6170-99-8414 and
3 Forensics Science International 2910 (2000) pages 1-18, also found that when the membrane of a
4 commercially available sweat patch was tested for the passage of externally applied materials
5 (CFWO), drugs in the uncharged state rapidly penetrated the membrane of the patch, but those in
6 the charged state were greatly slowed. In basic media, detectable concentrations of cocaine,
7 methamphetamine and heroin were observed at the earliest collection time after drugs were
8 placed on the outside of the membrane, at approximately 30 seconds. Drug concentrations
9 increased over a two hour time course, when the amounts detected represented 5-17% of the
10 drugs deposited on the surface of the sweat patch. Figure 1 depicts the rapid penetration of drugs
11 through the membrane from the outside when placed in slightly basic media such as sodium
12 bicarbonate (pH 8.3).

13 Additionally, Kidwell et al, in Susceptibility of PharmChek™ Drugs of Abuse Patch to
14 Environmental Contamination, NRL Memorandum Report NRL/MR/6170-99-8414 pages 12-
15 15, and Cocaine Detection in a University Population by Hair Analysis, Forensic Sci. Int., 84
16 (1997) pages 75-86 demonstrated that drugs externally applied to human skin bound readily.
17 Drugs deposited on the skin of drug-free volunteers several days prior to the application of the
18 sweat patch were not completely removed by normal hygiene or the cleaning procedures
19 recommended before application of the sweat patch. Even six days of normal hygiene did not
20 remove all drugs from externally contaminated skin and resulted in positive sweat patch tests.

21 Figure 2 depicts an experiment by Kidwell and Smith where drugs were placed on five

1 areas of skin and patches were applied at various times, days after the drug application, and with
2 varying amounts of normal hygiene. All sweat patches showed CFWI. Sweat patch
3 concentrations of all drugs applied to the skin generally decreased over time, with a few data
4 points showing variability from this trend. Even when the patch was applied seven days after
5 skin contamination with drugs, cocaine, BE, heroin, and methamphetamine were deposited in the
6 pad. Sources of variability may include the extent of normal hygienic cleansing, the placement
7 of the sweat patch over the contaminated area, and the effects of exercise on active sweating.
8 Drug concentrations in skin swabs taken just prior to patch applications (pre-patch swabs)
9 tapered off with time after contamination. By day 6, only one pre-patch swab contained
10 significant quantities of drugs. Concentrations of drugs decreased between the post-swab after
11 patch #1. (Several post-patch alcohol swabs were lost.) These results show that it is possible for
12 an individual to be externally contaminated with these drugs on one day, perform normal
13 hygienic washing for at least six days, cleanse the skin twice with 70% isopropyl alcohol swabs,
14 and still test positive for cocaine, heroin, and methamphetamine in the sweat patch.

15 Potential sources of drug contamination for CFWI and CFWO are plentiful. Cocaine in
16 particular and also methamphetamine, are found on paper currency, see J.C. Hudson, Analysis of
17 currency for cocaine contamination, *Can. Soc. For. Sci.*, 22, 203, 1989, J. Oyler et al, Cocaine
18 Contamination of United States Paper Currency, *J. Anal.Toxicol.*, 20 (1996) 213-216, and A.
19 Negrusz et al, Detection of Cocaine on Various Denominations of United States Currency, *J.*
20 *Forensic Sci.*, 43 (1998) 626-629. Although drugs on currency are hard to transfer to the skin,
21 they can transfer if the skin is moist, see D.A. Kidwell et al, Testing for Illicit Drugs via Sweat

1 and Saliva Analysis: Application to the Detection of Body Packers, in the Proceedings of the
2 1999 ONDCP International Technology Symposium, March 8-10, 1999, Washington, DC, pp.
3 21-15. This indicates the ease that drugs can spread through the general environment. Likewise,
4 individuals whose environments are predicted to contain drug contamination show higher levels
5 of drugs on their skin, see A. Tracqui et al, The Detection of Opiate Drugs in Non Traditional
6 Specimens (Clothing): a Report of Ten Cases, J. Forensic Sci., 40 (1995) 263-265. Touching the
7 patch with one's hand is a natural reaction to materials on the body. Also, some court officers
8 consider it a violation if the patch peels-off. Thus, intentionally pressing on the patch to keep
9 adhered to the skin could also transfer drugs to the surface from the hands. Alternatively,
10 wearing a close-filling undershirt, contaminated with as little as microgram quantities of these
11 drugs, (above the patch), and sweating could transfer drugs to the surface of the patch. The
12 laboratory studies show that the potential for external contamination of skin (CFWI) as well as
13 contamination of the patch membrane (CFWO) can occur and generate false positive results.
14 The exact percentage and degree of drug contamination in specific environments is generally not
15 known. To the extent that drugs must pass through the human body to produce metabolites,
16 metabolites can increase the reliability of a positive result. Unfortunately, for cocaine the major
17 metabolite, benzoylecgonine, is present to a small extent in street-grade cocaine (see J.F. Casale
18 et al., A Chromatographic Impurity Signature Profile Analysis for Cocaine using Capillary Gas-
19 Chromatography, J. Forensic Sci. 36 (1991) pages 1312- 1330) and appears to be produced by
20 cocaine degradation on the skin. In contrast, amphetamine is the major metabolite of
21 methamphetamine and is less likely present in illicit methamphetamine preparations.

1 Nevertheless, amphetamine is sometimes sold as methamphetamine and thus may contaminate
2 the environment. Contamination may also come from the sweat of prior use. Because the
3 individual being tested may still reside in the same location, wear clothing, or contact other drug
4 users, this contact may put that individual in proximity to metabolites generated from other
5 people or at prior times. Contact with metabolites may be ruled out based on the circumstances
6 of the subject's environment but contact with the parent drug could still be a possibility
7 Thus, the studies show that the potential for external contamination of skin (CFWI) as well as
8 contamination of the patch membrane (CFWO) can occur and generate false positive results.

9 The current scheme to detect tampering in the commercially available patch according to
10 the product literature is to conduct a visual inspection of the patch before it is removed to
11 determine if it is undisturbed and if the membrane has any holes. A single pinprick is very
12 difficult to detect with a visual inspection, yet can still allow the introduction of foreign
13 substances through pressure injection. Base would degrade cocaine to ecgonine, a compound
14 not normally detectable by immunoassays or by gas chromatography and mass spectrography,
15 and thus allow a cocaine user to escape detection. Heroin and methamphetamine would not be
16 degraded to undetectable products and consequently users of these drugs would not generate false
17 negatives.

18 The current sweat patches do not adequately prevent CFWO. Additionally, the current
19 methods for using the sweat patch do not adequately indicate the possibility of CFWI. Further,
20 the current sweat patches and methods for their use do not adequately detect tampering.

21 Therefore, there is a strong need for sweat patch devices and methods of using sweat patch

1 devices that reduce CFWO and detect and reduce CFWI thus producing more accurate and
2 reliable results, and also allow for easier detection of tampering.

3
4 **Summary of the Invention**

5
6 Accordingly, it is an object of the present invention to provide devices and methods for
7 collecting chemicals and biochemicals in perspiration for analysis whereby CFWO is reduced.

8 It is an object of the present invention to provide devices and methods for collecting
9 chemicals and biochemicals in perspiration whereby CFWI is reduced and/or detected.

10 It is a further object of the present invention to provide devices and methods for
11 collecting chemicals and biochemicals in perspiration for analysis in which tampering is more
12 easily detected.

13 Additional objects and advantages of the invention will be set forth in part in the
14 description which follows , and, in part, will be obvious from the description, or may be learned
15 by practice of the invention.

16 The foregoing objects of the present invention are achieved by providing a device and
17 method for collecting drugs and other biochemicals or chemicals in perspiration to provide for
18 increased accuracy of test results by decreasing CFWO, decreasing and detecting CFWI, and
19 more easily detecting tampering.

20 The present invention comprises a multilayer device, minimally including a membrane
21 which allows water vapor and air to escape, an absorbent pad for collecting the perspiration, and

1 an air gap between the membrane and the absorbent pad. Substances may be incorporated into
2 the device to allow for easy detection of tampering. Additional layers may be present in the
3 device.

4 Alternatively, the device can include a second membrane layer between the absorbent pad
5 and the first membrane layer, with an air gap between the first membrane layers and the
6 absorbent pad layer, either above or below the second membrane layer. Two membranes would
7 reduce the chance of flooding of the air gap with sweat during periods of heavy exercise.
8 Flooding in a one membrane device could allow contact of membrane with the exterior surface
9 and potentially permit CFWO. Substances may be incorporated into the device to allow for easy
10 detection of tampering.

11 Another aspect of the invention is a method for detecting CFWI, having the steps of
12 cleansing the skin with a swab, and saving the used cleansing swab for later analysis.

13
14 **Brief Description of the Drawings**

15
16 These and other objects and advantages of the invention will become apparent and more
17 readily appreciated from the following description of the preferred embodiments, taken in
18 conjunction with the accompanying drawings of which:

19 Fig. 1 is a chart showing how rapidly drugs penetrate the membrane from the outside
20 when placed in slightly basic media such as sodium bicarbonate (pH 8.3) showing the diffusion
21 of drugs places on the outside of patches.

1 Fig. 2 depicts an experiment where drugs were spiked on five areas of skin and patches
2 were applied at various times, days after the drug application, and with varying amounts of
3 normal hygiene. All sweat patches showed CFWI. Sweat patch concentrations of all drugs
4 applied to the skin generally decreased over time, with a few data points showing variability from
5 this trend. Even when the patch was applied seven days after skin contamination with drugs,
6 cocaine, BE, heroin, and methamphetamine were deposited in the pad. The top graph is a
7 summary of the experiment and the bottom two bar charts summarize the analysis results.

8 Fig. 3 is a schematic representation of a one-membrane device. The device has a
9 membrane layer (10) and an absorptive pad layer (40) separated by an air gap (20).

10 Fig. 4 is a cross section of the one membrane device of Fig. 3. The device has a
11 membrane (10) and an absorptive pad layer (40) separated by an air gap (20).

12 Fig. 5 is a cross-section of a two membrane device. The device has a first membrane
13 layer (10) and a second membrane layer (50) separated by an air gap (20). An absorbent pad (40)
14 is located under the second membrane layer (50).

15 Fig. 6 is a table representing the results of an experiment wherein 5 μ g of cocaine, heroin,
16 amphetamine, methamphetamine, and MDMA were placed on the arms of human volunteers.
17 The drugs were left overnight, followed by a hygienic shower in the morning, then the arms were
18 cleansed twice with 70% isopropanol, and the sweat patches were applied. The patches either
19 had absorptive pads made from Whatman 3 MM Chromatography paper or the Ansys cation
20 exchanger described below in the preferred embodiments section. The patches were worn for 3
21 days, and the table of Figure 7 presents the results.

1 **Description of the Preferred Embodiments**

2
3 Sweat patches were constructed using a membrane layer, which allows air and water
4 vapor to escape from the sweat patch, and an absorbent filter paper pad used for absorbing
5 perspiration. The sweat patch contained an air gap maintained by a screen between the absorbent
6 pad and the membrane . The patches was wetted with artificial sweat internally and externally,
7 then placed in a drug vapor chamber. Specifically, the patch was constructed using 3M
8 Tegaderm™ dressings (National Drug Code (NDC) 8333-1624-05) as the membrane and a
9 Whatman #3 filter paper pad. The patch was then exposed to drug vapors. The patch reduced
10 CFWO for cocaine by 98% as compared to a similarly constructed patch without the air gap and
11 screen.

12 An alternative design where the permeable membrane does not cover the entire spacer.
13 The remaining portion of the patch can be covered by a non-permeable membrane, as only
14 enough permeable membrane is needed to allow for water evaporation from the patch. This
15 design could decrease the cost of manufacturing the patch.

16 An alternative sweat patch design would provide a second membrane between the first
17 membrane and the absorbent pad. The two membrane design would reduce the chance of
18 flooding where the air gap fills with sweat during heavy exercise. Flooding could allow for
19 contact of the membrane in a single membrane device with the exterior surface and potentially
20 allow external contaminants into the patch.

21 An alternative sweat patch design would provide a second membrane between the first

1 membrane and the absorbent pad. An air gap separates the absorbent pad and the first
2 membrane, either above or below the second membrane.

3 An alternative design of the sweat patch would provide a second membrane between the
4 first membrane and the absorbent pad, the two membranes being separated by an air gap. The air
5 gap is maintained by a spacer. The spacer can be a second absorbent pad to absorb CFWO,
6 which may be tested if the results of the sweat patch test are questioned. The presence of a large
7 amount of drugs in the second absorptive pad (used for absorbing CFWO) may be grounds to
8 reject a positive finding as some of these drugs could leak into the first absorbent pad used to
9 absorbing perspiration.

10 An alternative sweat patch design would provide a second membrane between the first
11 membrane and the absorbent pad. An air gap separates the absorbent pad and the first
12 membrane, either above or below the second membrane. The air gap is maintained by a spacer.

13 An alternative design for the device contains a spacer that maintains the air gap.

14 Alternatively the spacer that maintains the air gap is composed of a material that allows
15 air and water vapor to pass yet maintains an air gap between the membrane and the absorbent
16 pad.

17 Alternatively, the material of the spacer is screen, mesh, fiberglass, woven material or
18 other fibrous material that maintains an air gap between the membrane and absorbent pad.

19 An alternative design for the sweat patches contains substances for the detection of
20 tampering. At least one compound acting as an internal standard is incorporated into the patch
21 and tested in the laboratory when the patch itself is tested. These substances are easily

1 incorporated into the device by placing a small quantity of the substance on the absorbent pad
2 used for collecting perspiration or on the spacer. The quantity of the substance is the amount of
3 substance corresponding to the midrange of the cut-off values used for assaying that particular
4 drug. For example, if the cut-off value for cocaine is 25 ng per patch, then incorporate 50 - 100
5 ng per patch of the substance into the patch. The cut-off value is the quantity of drug that the
6 testing laboratory determines indicates a positive test result. The substance should behave in a
7 similar manner as the chemicals or biochemicals being tested for, under such conditions as are
8 present when tampering with the device is attempted, for example when the pH is changed in the
9 patch, an oxidant is added to the patch, or light and heat are applied to the patch

10 An alternative design for the sweat patches contains substances for the detection of
11 tampering. A substance such as a drug homolog could be tested in the laboratory at the same
12 time the patch was being tested for the chemical and biochemical substances. These homologs
13 are easily incorporated into the device by placing a small quantity of the homolog on the
14 absorbent pad used for collecting perspiration or on the spacer. The quantity of the homolog is
15 the amount of homolog corresponding to the midrange of the cut-off values used for assaying
16 that particular homolog. If the homolog was intact, then no tampering would have occurred.
17 Methyl-p-methylbenzoyl ecgonine is an example of a drug homolog for cocaine.

18 An alternative design for the sweat patches contains substances for the visual detection of
19 tampering. A substance such as a masked pH indicator such as acetylated bromocresol purple
20 (BCP) is incorporated into the patch. If BCP is acetylated with a carboxylic acid, the acetylated
21 BCP is a light yellow. Upon cleavage with base, the acetylated BCP returns to BCP which is

1 purple above pH6. If the sweat patch has been tampered with by injection of a foreign
2 substance, the color of the patch would be altered. The amount of indicating substance to be
3 incorporated could vary to produce a level of color indication detectable to the human eye.
4 Foreign substances frequently used to tamper with these devices are basic materials which
5 degrade certain drugs of abuse.

6 An alternative design for the sweat patches contains substances for the visual detection of
7 tampering. A substance such as an oxidation reagent can be tested for by incorporation of a
8 number of colorimetric dyes. ABTS (2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) or
9 Tetramethylbenzidine (TMB) are examples of oxidation reagents that are useful for this purpose.
10 Foreign substances frequently used to tamper with these devices are oxidants, which degrade
11 certain drugs of abuse.

12 Alternatively, the substance for the detection of tampering with the device is incorporated
13 into either the absorbent pad or the spacer of the device.

14 Alternatively, the absorbent pad may contain at least one functionality which binds the
15 substances being detected via ionic or hydrophobic bonds. The absorbent pad may be comprised
16 of several layers, each with a separate functionality. Such functionalities may be synthetic small
17 molecules or proteins, including antibodies, antibody fragments or receptors. An example is
18 glass fiber discs embedded with bonded silica, where the bonded silica is bonded with a strong
19 cation exchanger. Such material is produced by Ansys Diagnostics, Inc. An advantage of such
20 an absorbent pad can be seen in Fig. 6. 5 μ g of cocaine, heroin, amphetamine, methamphetamine,
21 and MDMA were placed on the arms of human volunteers. The drugs were left overnight,

1 followed by a hygienic shower in the morning, then the arms were cleansed twice with 70%
2 isopropanol, and the sweat patches were applied. The patches either had absorptive pads made
3 from Whatman 3 MM Chromatography paper or the Ansys cation exchanger described above.
4 The patches were worn for 3 days, and the table of Fig. 6 presents the results. Further examples
5 of absorbent pad materials would be sulfonated cellulose, as disclosed in Gujral, et al, U.S.
6 Patent No. 5,907,037, issued May 25, 1999, and Shet, U.S. Patent No. 5,522,967, issued June 4,
7 1996, both incorporated herein by reference, or phosphate derivatized cellulose (P-81) produced
8 by Whatman as chromatography media.

9 Although a few embodiments of the present invention have been shown and described, it
10 would be appreciated by those skilled in the art that changes may be made in these embodiments
11 without departing from the principles and spirit of the invention, the scope of which is defined in
12 the claims and their equivalents.

Docket No.: N.C. 80,182
Inventor's Name: David A. Kidwell

PATENT APPLICATION

1
2
3 ABSTRACT
4

5 The invention is useful for providing sweat collecting devices for the detection of
6 chemicals or biochemicals in the perspiration of a living subject while reducing drug
7 contamination from without (external sources), and for detecting tampering of the sweat
8 collection device. The invention also provides a method for using the sweat collecting device
9 which reduces and identifies prior chemical or biochemical contamination on the skin of the
10 tested subject.
11
12

Fig. 1





Fig. 2






Fig. 3




Fig. 4




Fig. 5

Fig. 6

Absorbent Pad Material	ng/patch Cocaine	ng/patch Heroin	ng/patch Amphetamine	ng/patch Methamphetamine	ng/patch MDMA
Whatman 3 MM Chromatography paper	27	42	21	22	17
Ansys Diagnostics, Inc. glass fiber discs embedded with bonded silica, where the bonded silica is bonded with a strong cation exchanger	106	32	51	60	93